Listing of the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A method for reducing insulin and/or glucose plasma levels in a subject afflicted with diabetes, comprising administering to the subject an effective amount of dried ~~Dunaliella~~ *Dunaliella* algae, thereby reducing the subject's plasma insulin and/or glucose plasma levels.

2. (Cancelled)

3. (Currently amended) The method according to claim 1 wherein the dried ~~Dunaliella~~ *Dunaliella* algae is administered together with one or more activators of nuclear receptors.

4. (Original) The method according to Claim 3 wherein the activators of nuclear receptors are peroxisome proliferator-activated receptor α or γ (PPARα or PPARγ) agonists.

5. (Previously presented) The method according to Claim 4 wherein the PPARα or PPARγ agonists are selected from the group consisting of fibrates and thiazolidinediones.

6. (Previously presented) The method according to Claim 5 wherein the fibrates are selected from the group consisting of clofibrate, fenofibrate, bezafibrate, ciprofibrate, beclofibrate, and gemfibrozil.

7. (Previously presented) The method according to Claim 5 wherein the thiazolidinediones are selected from the group consisting of troglitazone, BRL 49653, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone, and rosiglitazone.

8. (Currently amended) The method according to Claim 1 wherein the dried ~~Dunaliella~~ *Dunaliella* algae is administered orally.

9. (Currently amended) The method according to Claim 1 wherein the dried ~~Dunaliella~~ *Dunaliella* algae is obtained from ~~Dunaliella bardawil~~ *Dunaliella bardawil.*

10. (Previously presented) The method according to Claim 1, wherein the dried ~~Dunaliella~~ *Dunaliella* algae is encapsulated.

11-27. (Cancelled)

28. (Currently amended) The method according to claim 1, wherein the dried ~~Dunaliella~~ *Dunaliella* algae comprises β-carotene.

29. (Previously presented) The method according to claim 28, wherein the β-carotene comprises 9-cis β-carotene.

30. (Previously presented) The method according to claim 28, wherein the β-carotene comprises an approximately 1:1 ratio of all-trans β-carotene and 9-cis β-carotene.